13/12/2022 – AB Science announced that it has received a Notice of Deficiency (“NOD”) for its masitinib New Drug Submission in the treatment of amyotrophic lateral sclerosis Download PDF Post navigationPreviousPrevious post:AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNextNext post:AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankRelated PostsAB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisDecember 29, 2022Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in SwitzerlandDecember 27, 2022AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankDecember 22, 2022AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022Revenues for the first half of 2022 and update on AB Science’s activitiesSeptember 30, 2022
AB Science has received approval from the U.S. Food and Drug Administration (FDA) to initiate the confirmatory Phase 3 study with masitinib in the treatment of progressive multiple sclerosisDecember 29, 2022
Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in SwitzerlandDecember 27, 2022
AB Science announces the drawdown of the first tranche of 6 million euros under its financing agreement with the European Investment BankDecember 22, 2022
AB Science receives U.S. Food and Drug Administration (FDA) authorization to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s DiseaseNovember 21, 2022
AB Science receives first agencies authorizations to initiate confirmatory Phase 3 clinical study with masitinib in the treatment of Alzheimer’s diseaseOctober 10, 2022
